A phase 2a, open-label study of visilizumab for treatment of perianal fistulas in patients with Crohn's disease.
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2012
At a glance
- Drugs Visilizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors PDL BioPharma
- 06 Mar 2012 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 29 Jul 2011 Additional trial identifier 65243779 and trial centres identified and planned patient number is 20 as reported by ISRCTN: Current Controlled Trials record.
- 27 Jul 2011 New source identified (ISRCTN: Current Controlled Trials record)